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Abstract: This study delineates the regulatory effects of
inflammatory cytokines on mononuclear phagocyte plas-
minogen activator (PA) activity. The mechanisms by
which mononuclear phagocytes modulate PA activity are
described. Mononuclear phagocytes regulate net PA ac-
tivity by the balanced expression of urokinase-type PA
( uPA), in either secreted or membrane-associated forms,
and a specific plasminogen activator inhibitor, PAI-2.
Therefore, understanding how immunomodulators regu-
late macrophage PA activity requires that the compara-
tive effects of uPA and PAI-2 be elucidated. We deter-
mined how recombinant interferon-y (IFN) and tumor
necrosis factor-a (TNF) regulate plasminogen activation
in monoblast-like U937 cells and normal human mono-
cytes. In U937 cells, both IFN and TNF induced concur-
rent increases in secreted PA and PA inhibitor activities.
These effects were accompanied by increased immuno-
reactive uPA and PAI-2 in conditioned media (enzyme-
linked immunosorbent assay) and steady-state levels of
cellular uPA and PAI-2 mRNA (Northern analysis). To
determine the relative abilities of IFN and TNF to either
promote or inhibit plasmin generation, we directly com-
pared the effects IFN and TNF, using optimal stimulating
concentrations. IFN induced PA activity to 180% of the
level achieved by TNF. In contrast, IFN elicited only
78% of the PA inhibitor produced by TNF stimulation.
These differences in secreted activity can be explained by
the shift in balance between uPA and PAI-2 proteins. Im-
munoreactive uPA was induced equally by IFN and TNF,
but TNF generated higher levels of PAI-2. The same over-
all pattern of results was seen in normal human mono-
cytes. IFN and TNF differ greatly in the ability to aug-
ment receptor-bound PA activity in U937 cells, as IFN
induced a twofold increase but TNF had no effect. We
conclude that IFN and TNF modulate mononuclear
phagocyte proteolytic activity through coordinate regula-
tion of secreted and receptor-bound uPA, balanced against
concurrent expression of PAI-2. These effects are cyto-
kine specific, as IFN is superior to TNF in stimulating
expression of both secreted and receptor-associated PA ac-
tivities. These properties suggest mechanisms by which
mononuclear phagocytes control proteolysis in cytokine-
rich inflammatory foci. J. Leukoc. Biol. 31: 256-263;
1992.
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INTRODUCTION
Substantial evidence indicates that plasmin formation through
the action of plasminogen activators (PAs) is crucial for the
orderly generation and resolution of inflammation [13].
Mononuclear phagocytes are the dominant source of PA
activity among leukocytes [13]. During recruitment, mono-
nuclear phagocytes utilize urokinase-type plasminogen acti-
vator (uPA) to focus piasmin activity in the immediate pen-
cellular environment, thereby effecting sufficient extracellular
matrix degradation to permit migration across tissue planes
[16, 26]. Plasmin is believed to be important in inflammatory
tissue remodeling through its degradation of provisional
fibrin-fibronectin matrices and many of the glycoprotein
constituents of basement membranes [13]. Some immuno-
modulatory effects of uPA are indirect, as uPA has been
shown to be a chemotactic factor for polymorphonuclear leu-
kocytes and a lymphocyte mitogen [5, 7]. Further, uPA acti-
yates some cytokines, such as tumor necrosis factor (TNF),
transforming growth factor 3, and interleukin-!, but macti-
yates others, such as interferon--y (IFN) [24, 25, 31, 37].
Thus, the expression of PA activity is intimately involved in
the course of the inflammatory response by directing inflam-
matory cell trafficking, matric remodeling at the inflamma-
tory site, and cytokine-mediated cell-to-cell signaling.
Because expression of macrophage PA activity affects so
many aspects of the inflammatory response, it is necessary to
understand how this system is regulated. These mechanisms
are undoubtedly complex, as mononuclear phagocytes cx-
press not only uPA and a plasma membrane receptor for
uPA (uPAR) but also a PA inhibitor (PAI-2) [4, 41]. It ap-
pears that mononuclear phagocytes have the capacity to
modulate expression of each component of the PA system in-
dependently. We have shown, for example, that uPA and
PAI-2 synthesis can be modulated in either parallel or diver-
gent fashion depending on the agonist used [19, 28]. Agonist-
specific effects on uPA binding sites have also been shown
[ 27]. The net expression of mononuclear phagocyte PA ac-
tivity, however, is a reflection a dynamic balance of these,
highly interactive proteins. Therefore, examining one of
these proteins in isolation is insufficient. Instead, it is essen-
tial to adopt a more integrated approach in which changes
in PA activity are assessed in the context of concomitant,
changes in PA inhibitor activity.
The factors in the inflammatory milieu responsible for
regulating macrophage. PA activity remain poorly character-
ized. Cytokines likely provide important regulatory signals
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for macrophage PA activity. PA activity is expressed abnor-
maliy in vivo in inflammatory lung disease, such as sarcoido-
sis, in which cytokines are pathogenetically important {3,
20]. In vitro, stimuiated lymphocytes stimulate net macro-
phage PA activity, but the mechanisms are unclear because
individual effects on uPA, PAI-2, and uPAR were not de-
scribed [18, 40]. Conversely, inflammatory cytokines and
hematopoietic growth factors have been shown to induce
changes in either PA, PA inhibitor, or uPAR in isolation, but
the effects of these mediators on the relative balance between
these components has not been delineated [9, 27, 32, 36]. Ac-
cordingiy, it is not known whether individual cytokines affect
net PA activity or the components of the PA system in an
agonist-specific manner. To determine whether there is cyto-
kine specificity in the regulation of the mononuclear phago-
cyte PA system, we compared the effects of IFN and TNF on
the relative expression of PA and PA inhibitor activities in
human mononuclear phagocytes. We specifically examined
the regulatory effects of these inflammatory cytokines on




Plasminogen was prepared from outdated human plasma by
lysine-Sepharose affinity chromatography (Pharmacia Chem-
icals, Piscataway, NJ) [14]. Plasminogen preparations were
rendered free of active plasmin by treatment with phenyl-
methylsulfonyl fluoride (1 mM) for 16 h at 25#{176}C,followed by
extensive dialysis in 0.05 M phosphate buffer, pH 7.5. The
human PAI-2 cDNA, generously provided by Andrew C.
ebb (Department of Biological Sciences, Weilesley College,
ellesiey, MA), was the subcioned internal PstI-DraI frag-
ent ofthe pcD-1214 clone in pGEM-2 (Promega, Madison,
I), inserted between the PStI and SmaI sites in the poly-
inker [42]. Human urokinase cDNA was obtained from the
apanese Center Resources Bank-Gene, National Institute of
eaith, Tokyo [34]. This is a nearly full-length clone inserted
n the PstI-PvuII site of pcD. Culture medium and additives
crc found to contain less than 0.1 endotoxin unit/mi, as de-
ermined by a Limulus amebocyte lysate assay (Whittaker
ioproducts, Walkersville, MD).
solation of Monocytes
uman peripheral blood monocytes were purified from
uffy coats provided by the American Red Cross, Detroit,
I. Buffy coats were diluted 1:1 with 5 mM EDTA-normai
aline and purified by density gradient centrifugation through
ymphoprep (Nycomed AS, Oslo, Norway). After washing
he RPMI-1640 (Gibco, Grand Island, NY), cell number was
etermined by counting in a hemocytometer and viability
as assessed by trypan blue exclusion. Differential cell
ounts were determined by examining Giemsa-stained cyto-
entrifuge samples. The mononuclear cells were resuspended
t 2 x 106 cells/mI in complete medium consisting of
PMI-1640 supplemented with penicillin (100 U/mi), strep-
omycin (100 g/ml), gentamicin (100 pg/mi), L-glutamine
2 mM), and 5% fetal bovine serum (Hyclone, Logan, UT),‘nd the monocytes were purified by adherence in 16-mm
lastic dishes (Corning, Corning, NY) at 5 x 106 cells/well
approximately 2 x 106 monocytes) for 2 h in humidified air
ontaining 5% CO2 at 37#{176}C. Nonadherent cells were re-
noved by washing with RPMI-l640 at 37#{176}C.and adherent
:elis were cultured in complete medium or serum-free
nedium as indicated below.
U937 Cell Culture
U937 cells (American Type Culture Collection, Rockville,
MD) were maintained in complete medium in humidified
air containing 5% CO2 at 37#{176}C.Cells were routinely pas-
saged into 50 ml of fresh medium by seeding 5 x 106 cells
into 75-cm2 tissue culture flasks (Corning) at 3- to 4-day in-
tervais. Cells were always passaged 24 h before stimulation
with cytokines.
Preparation of Cells for Determination of PA and
PA Inhibitor Activities
U937 cells were washed extensively in RPMI-1640 and sus-
pended in serum-free medium supplemented with 0.1%
(w/v) bovine serum albumin (BSA; Sigma Chemical Co., St.
Louis, MO), dispensed (106 in 1 ml) in sterile 12 x 75 mm
polypropylene tubes (Falcon, Lincoin Park, NJ), and in-
cubated with varying concentrations of recombinant IFN
and TNF (Genzyme, Boston, MA). After 24 h, cells and
conditioned media were separated by centrifugation. The PA
and PA inhibitor activities of the conditioned media were
then determined by esterolytic assays. The cells were washed
extensiveiy with RPM!, counted, and used immediately to
measure receptor-bound uPA activity (see below).
Adherent monocytes were cultured in serum-free medium
supplemented with 0.1% human serum albumin (American
Red Cross) for 24-48 h with varying doses of IFN and TNF.
The conditioned media were then removed and the PA and
PA inhibitor activities detemrined by esterolytic assays. As
an internal quality control for each experiment, monocytes
were cultured in parallel wells with 10 ng/mi phorhol
myristate acetate (PMA) to ensure that there was the ex-
pected increase in PA inhibitor activity [35]. On occasion,
cells were refractory to PMA and were considered to be
either endogenously activated or injured during purification.
Data derived from these cell preparations were not used.
Determination of Receptor-Bound PA
To quantitate the uPA activity associated with the plasma
membrane uPAR, U937 cells were washed extensively with
RPMI-1640. To dissociate the uPA from its receptor, cells
were then treated with 50 mM glycine, 100 mM NaCl, pH 3,
for 3 mm, 0#{176}C,at 3 x 106 cells/mi [4, 39]. A 40% volume
of neutralizing buffer (0.5 M HEPES, 100 mM NaCI, pH 7.5)
was then added. As a control, cells were treated with a neutral
buffer consisting of 50 mM glycine, 100 mM NaC1, pH 7.4.
The neutral buffer did not displace detectable PA activity
(data not shown). Samples were centrifuged, and the super-
natant was assayed for PA activity as detailed below.
Esterolytic Assays for PA and PA Inhibitor Activities
Plasminogen activator activity was measured with the estero-
lytic assay of Coleman and Green, with minor adaptations
for use in 96-well plates [8]. Test samples (10 &l) were mixed
with an optimal amount of plasminogen in 0.67 M glycine,
0.17% BSA, 1.7 tM Tris, 0.02% triton X-100 (50 jl) and in-
cubated at 37#{176}Cfor 30 mm. The plasmin generated by this
step was then quantified by addition of the synthetic plasmin
substrate thiobenzyl benzyloxycarbonyl-L-lysinate (0.2 mM;
Calbiochem. La Jolla, CA) and a color reagent, 5,5’-
dithiobis 2-nitrobenzoic acid (2.2 mM; Calbiochem) in
200 l of 0.2 M phosphate, 0.2 M NaCl, 1% Triton X-100.
After 30 mm at 37#{176}C,optical absorbance was read at 414 nm
with a muitichannel spectropliotometer  Flow Laboratorles.
McLean, VA). Alter subtracting control values of wells lack-
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Fig. 1. PA and PA inhibitor activities of IFN-stimulatcd U937 cells. IFN induced a dose-related increase in both PA (left) and PA inhibitor (right) activities.
PA activity is expresserl in milliPloug units (mPU) and PA inhibitor in PAL units (1 PAl unit = I mPU inhibited). PA: P < .05; **P < .001. PA inhibitor:
*P < .01; P < .005.
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curve generated with commercially prepared urokinase (Cal-
biochem) and expressed in milliPloug units (mPU).
Because uPA is secreted as a proenzyme, stable complexes
with PAI-2 do not form in conditioned media until ex-
ogenous plasminogen is introduced in the first phase of the
esterolytic assay [41]. Therefore, by modifying the esterolytic
assay, we can measure either PA or PA inhibitor activity in
conditioned media. To measure PA inhibitor activity, serial
dilutions of the test samples were coincubated with 2 mPU
of urokinase and the residual PA activity was measured in
standard fashion. PA inhibitor activity was calculated from
a plot of the sample concentration (reciprocal of the dilution
factor) versus residual PA activity and expressed as PA in-
hibitor units/ml (1 PAl unit = 1 mPU PA inhibited). En-
dogenous PA activity was included with the exogenous 2
mPU when calculating PA inhibition.
uPA and PAI-2 Antigens
Levels of immunoreactive uPA and PAI-2 in 24-h conditioned
media were measured using Tint-Elize-uPA and Tint-Elize-
PAI-2 enzyme-linked immunosorbent assay (ELISA) kits ac-
cording to manufacturer’s directions (American Diagnostica,
Greenwich, CT).
mRNA Analysis
For these experiments, U937 cells were cultured in serum-
containing medium (2.2 x l0 in 50 ml) in 75-cm2 flasks in
the presence or absence of IFN (0-1000 U/ml) and TNF
(0-500 U/mi) for periods ranging from 0.5 to 12 h. Cells were
washed with RPMI-1640 and flash frozen at - 70#{176}C.To ex-
tract cellular RNA, cell pellets were sonicated on ice in urea
(5 M), LiCl (3 M), and heparin (14 U/ml), according to the
method ofAuffray and Rougeon [1]. RNA was pelleted after
overnight precipitation at - 20#{176}Cand extracted repeatedly
with phenol-chloroform. The aqueous layer was precipitated
with ethanol-Na acetate at -20#{176}C. The RNA pellet was
suspended in RNAase-free water and concentration deter-
mined by spectroscopy at 260 nm.
Human monocytes were purified from mononuclear cells
by adherence to 60-mm plastic tissue culture dishes (Corn-
ing). Mononuclear cells (2 x 107) were plated, routinely
yielding 8 x 106 monocytes/dish. The adherent monocytes
were incubated for 4 h in serum-containing medium in the
presence and absence of IFN (1000 U/ml) and TNF (500
U/ml). The medium was then removed and the monocytes
lysed directly in the culture dish by repeated pipet aspiration
in 4.23 M guanidine isothiocyanate (IBI, New Haven, CT),
0.5% sarcosyl, 25 mM citric acid, and 0.72% 2-mercapto-
ethanol. The RNA was purified by phenol-chloroform ex-
traction and precipitation at - 70#{176}Cin isopropanol-Na ace-
tate [6] and quantitated as above.
The RNA was size fractionated electrophoretically on 1%
agarose gels containing 3.5 tM formaldehyde and 20 pg/mi
ethidium bromide [30]. Visualization of ribosomai bands
under ultraviolet (UV) light provided internal size markers
for each lane and also confirmed that the RNA content was
equal in corresponding lanes. The RNA was transferred to
Hybond nylon filters (Amersham, Arlington Heights, IL)
according to the method of Southern and fixed by exposure
to UV light [30]. The cDNA of interest was labeled with
[32P]dCTP (Amersham) by random priming, achieving
specific activities of approximately 5 x 108 cpm/g DNA
[17]. The nylon filters were then hybridized with 2 x 10’ cpm
of [32P]cDNA for 18 h at 65#{176}C,followed by serial washes of
increasing stringency, the final wash consisting of 0.1 x stan-
dard saline citrate (0.15 M NaCl/0.15 M Na citrate), 0.1% so-
dium dodecyi sulfate at 68#{176}C[30]. The filters were then de-
veloped by autoradiography, using Kodak XAR-5 X-Omat
AR film at - 70#{176}C(Eastman Kodak, Rochester, NY).
Statistics
For experiments utilizing U937 cells, comparisons between
groups were performed using an unpaired Student’s I-test
F45]. Where appropriate, data were log transformed to en-
sure equivalent variances between groups. For experiments
utilizing peripheral blood monocytes, a paired Student’s t-
test was used to compensate for interdonor variability in the




U937 cells were always >95% viable at the onset of cytokine
stimulation. After incubation in serum-free medium for
24 h, cells were routinely >90% viable, even at the highest
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ig. 2. PA and PA inhibitor activities of TNF-stimulated U937 cells. TNF induced a dose-related increase in both PA and PA inhibitor activities. i)ata
re expressed as in Fig. 1. PA: P < .01; P < .001. PA inhibitor: P < .005.
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NF). Higher concentrations significantly reduced cell via-
ility in 24-h cultures. Mononuclear cells consisted of ap-
roximately 40% monocytes, and adherent cell preparations
ere routinely >94% monocytes and >95% viable. The
fects of cytokines and serum-free medium on monocyte
iability were identical to those observed in U937 cells.
ffects of IFN and TNF on PA and PA Inhibitor
ctivities of U937 Cells
) determine the effects of IFN on PA and PA inhibitor ex-
ession, conditioned media were assayed after incubation
r 24 h with 0-1000 U/mi IFN. Conditioned media of con-
ol cells consistently contained low levels of PA activity
4.7 ± 8.1 mPU/ml). IFN induced a marked increase in PA
tivity in a dose-dependent manner, reaching a maximum
1000 U/mi (391 ± 40.2 mPU/ml; P < .001) (Fig. 1). Con-
tioned media of control cells also showed activity when
sayed for PA inhibitor (25.8 ± 2.4 PAl units/ml). In
trailel with the increase in PA activity, IFN induced a dose-
pendent increase in PA inhibitor activity that reached a
aximum at 1000 U/mi (146.0 ± 46.2 PAl units/ml;
< .005) (Fig. 1).
Cells were stimulated with 0-500 U/mi TNF for 24 h to
termine the effects on secreted PA and PA inhibitor activi-
s. Conditioned media from control ceiis contained PA ac-
Tity (71.8 ± 10.0 mPU/mi). TNF increased PA activity in
dose-dependent manner, reaching a maximum at 500 U/ml
55.9 ± 11.4 mPU/mi; P < .001) (Fig. 2). TNF induced a
trallei increase in PA inhibitor activity, from control levels
. 25.8 ± 2.4 PAl units/mi to a maximum of 206 ± 83.4
) < .005) in response to 500 U/mi (Fig. 2). The maximal
crease in PA activity was significantly less than that achieved
r the highest concentration of IFN (P < .02). However, the
fference between the cytokines in maximally inducing PA
hibitor activity was not statistically significant.
To compare directly the effects of IFN and TNF on secreted
It and PA inhibitor activities, cells were stimulated in
trallel using a maximal concentration of either IFN (1000
/ml) or TNF (500 U/ml). IFN stimulation increased PA ac-
Tity to 180 ± 21.3% of the level produced by TNF (Fig. 3;
< .01). By contrast, IFN-induced PA inhibitor activity
as only 78 ± 11.7% of the activity induced by TNF
) = .15). Thus, the two cytokines differed markedly in alter-
ing the balance between secreted PA and PA inhibitor activi-
ties (P = .008; Fig. 3), with IFN producing a secretory
profile more amenable to fluid-phase plasminogen activation.
Measurement of uPA and PAI-2 Antigens
Macrophages secrete uPA in a zymogen form that is not in-
hibited by PAI-2 until it is activated by plasmin [41]. This
permits measurement of both PA and PA inhibitor activities
in conditioned media. When piasminogen is added in the
initial phase of the esterolytic assays, however, there is a
potential for forming uPA-PAI-2 complexes that do not con-
tribute to either net PA or PA inhibitor activities. We there-
fore used ELISA assays for uPA and PAI-2 to determine how
the results of the activity assays reflected changes in the reia-
tive balance between secreted uPA and PAI-2 proteins. We
stimulated U937 cells with maximal concentrations of IFN
and TNF (1000 and 500 U/mI, respectively) and assayed con-











Fig. 3. Comparative effects of IFN and TNF on secreted PA and PA inhibi-
tor activities in U937 cells. Activities induced in parallel cultures by IFN
(1000 U/mi) and TNF (500 U/mI) are expressed as a ratio (IFN/TNF). IFN
induced 180% of the PA activity produced by TNF (IFN/TNF >1;
P < .01). IFN elicited only 78% of the PA inhibitor activity produced by
TNF (IFN/TNF < I; P = .15). IFN/TNF (PA) * IFN/TNF (PA inhibitor);
P = .008.
:uPA (ng/mI) r- NS -  PAI.2 (ng/mI) 0.02
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Fig. 5. (A) Northern blot analysis of U937 cells incubated with IFN
U/mi) for 0-6 h. Filters were hybridized with a cDNA probe for
(2.4 kb; top) and PAI-2 (2.0 kb; bottom). IFN increases mRNA for
uPA and PAI-2, with the maximal increase occurring at approximately 6
(B) Northern blot analysis of U937 cells incubated with TNF (500
0-6. Filters were hybridized with a eDNA probe for uPA (top) and
(bottom). TNF increases mRNA for both uPA and PAI-2, peaking at
proximately 6 h.





Fig. 4. Effects of IFN and TNF on secretion of uPA and PAI.2 antigens by
U937 cells. IFN (1000 U/mi) and TNF (500 U/mi) induced significant in-
creases in uPA and PAI-2 antigens over unstimulated controls. IFN. and
TNF-induced uPA antigen levels were virtually identical, whereas TNF in-
duced significantly higher levels of PAI-2 antigen than did IFN (P < .02).
*P < .002;  P < .05.
the expression of functional activity, IFN and TNF induced
significant increases in both uPA and PAI-2 antigens (Fig. 4).
IFN and TNF produced equal levels ofuPA antigen. By con-
trast, the level of PAI-2 antigen secreted by IFN-stimuiated
cells was significantly lower than that induced by TNF
(P < .02). Therefore, IFN produces higher levels of net PA
activity than TNF because there is less offsetting inhibition
by PAI-2, not because uPA secretion is relatively enhanced.
This demonstrates that although IFN and TNF are alike in
increasing both uPA and PAI-2 levels, they differ significant-
ly in their modulation of the relative baiance of enzyme and
inhibitor and thus in their induction of net PA activity.
Effect of IFN and TNF on mRNA for uPA and PAI-2
We next determined whether IFN- and TNF-induced in-
creases in uPA and PAI-2 protein levels could be explained
by proportionate increases in steady-state mRNA levels.
Cells were incubated with either IFN (1000 U/ml) or TNF
(500 U/mI) for varying time intervals prior to lysis and RNA
extraction, as detailed in Materials and Methods. The same
filters, stripped and reprobed, were used for determination
of both uPA and PAI-2 mRNA. IFN induced substantial in-
creases in mRNA for both uPA and PAI-2 (Fig. 5A). Both
message levels peaked after stimulation for 4-6 h. The mes-
sage levels declined at similar rates, returning to near control
levels within 12 h. TNF also increased mRNA for both uPA
and PAI-2 over a similar time period (Fig. 5B). The increase
in uPA mRNA levels over controls was consistently smaller
in response to IFN than TNF, whereas the two cytokines in-
duced similar increases in PAI-2 mRNA. The same pattern
was seen with monocytes (Fig. 6; see below).
Effects of IFN and TNF on PA and PA Inhibitor
Expression by Monocytes
We sought to determine whether the results of experiments
with U937 cells accurately reflect the effects ofIFN and TNF
on authentic human mononuclear phagocytes. Like U937
cells, monocytes expressed secreted PA inhibitor activity that
increased from 63 ± 19 PAl units/ml in controls to 106 ± 33
(P < .05) in response to IFN (1000 U/mI) and to 167 ± 50
(P < .05) in response to TNF (500 U/mi) (Fig. 6). In con-
trast to U937 cells, PA activity was not detectable in any of
the monocyte supernatants. Extending the incubation times
to 48 h did not appreciably alter these results (data not
shown).
Monocytes were incubated with either IFN (1000 U/mi)
TNF (500 U/mi) for 4 h prior to lysis and RNA
In parallel with the PA inhibitor activity data, both IFN
TNF increased mRNA for PAI-2 (Fig. 6).
mRNA was consistently detectable under controi
IFN and TNF induced marked increases in uPA mRNA
were quite similar to the results obtained with U937
Thus, the apparent absence of PA activity in
conditioned media is likely due to a lower level of uPA
TNF thesis and a predominance of PAI-2 secretion, rather than
fundamental difference in uPA regulation between
cytes and U937 cells.
Determination of Receptor-Bound uPA
We further determined whether stimulation with IFN
TNF for 24 h also modulated the uPA activity bound to
rophage plasma membrane receptors. In parallel with
effects of IFN and TNF on secreted PA activity, we
that the cytokines had markedly different effects on
bound uPA of U937 cells. Even relatively low doses of
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Fig. 6. Effects of IFN and TNF on normal human monocytes. Stimulation
ofmonocytes with IFN increased secreted PA inhibitor activity. Stimulation
of monocytes with TNF also increased secreted PA inhibitor activity (left;
*P < .05). Data are expressed as in Fig. 1. Northern blot analysis (right)
shows that stimulation of monocytes with either IFN or TNF increases
mRNA for both uPA and PAI-2.
values (from 61.8 ± 15.3 mPU/1 x 106 cells to 117 ± 21.1;
P < .02) (Fig. 7). By contrast, TNF had no effect on
receptor-bound uPA activity, even at the highest doses used
(500 U/mi). These experiments were limited to U937 cells as
the leveis of PA activity that could be extracted from mono-
cytes by acid washing were not consistently above the detec-
tion limit of the esterolytic assay.
DISCUSSION
Mononuclear phagocytes control plasminogen activation by
combined expression of uPA, PAI-2, and the uPA receptor.
We have shown that macrophages can be induced to regulate
the uPA and PAI-2 genes in tandem or divergent fashion [19,
28]. The ability to regulate the components ofthe PA system
independently enables macrophages to express a broader
range of PA activity than would be possible if modulation of
uPA synthesis were inextricably linked to parallel changes in
PAI-2 synthesis. This also suggests that equivalent changes
in PA activity can be achieved mechanistically by a spectrum
ofconcomitant changes in uPA and PAI-2 expression. Clear-
ly, then, the overall regulation of macrophage PA activity
cannot be understood by isolated studies of uPA, PAI-2, or
the uPA receptor. In the present study, we investigated the
regulatory effects of IFN and TNF on the relative balance of
uPA and PAI-2 expression by mononuclear phagocytes.
Both IFN and TNF increased concurrent secretion of PA
and PA inhibitor activities (Figs. 1 and 2). Increased expres-
sion of uPA and PAI-2 adequately explains these functional
changes, as increased levels of uPA and PAI-2 antigens were
present in conditioned media (Fig. 4). These findings extend
previous observations that IFN can augment expression of
uPA mRNA in macrophages [9] and that in other cell types,
such as H1080 fibrosarcoma cells, TNF can augment PAI-2
synthesis [32]. This cytokine responsiveness is consistent
with the genetic structure ofthe uPA and PAI-2 genes, which
both contain AU-rich sequences in the 3’ untranslated
regions that are typically associated with rapid modulation
by inflammatory cytokines [2, 44].
It is important to note that the responses to IFN and TNF
were similar only to the extent that both cytokines caused
up-regulation ofuPA and PAI-2. When we compared the in-
creases elicited by IFN and TNF, substantial differences in
the magnitude of responses were revealed. IFN caused a sig-
nificantly greater increase in secreted PA activity than did
TNF (Figs. 1-3). However, PA inhibitor activity did not fol-
low this pattern, as the PA inhibitor actively elicited by IFN
was approximately 75% of the response to TNF (Figs. 1-3).
Clearly, modulation of the balance between PA and PA in-
hibitor activity is cytokine specific.
By examining synthesis ofuPA and PAI-2 proteins, we de-
termined the likely basis for the difference between IFN and
TNF in augmenting PA activity, IFN and TNF produced
identical increases in uPA secretion, but PAI-2 secretion was
significantly greater in response to TNF than IFN (Fig. 4).
Thus, the cytokine-specific effects on PA activity can be at-
tributed not to a direct effect on uPA expression, but rather
to differences in the counterreguiatory effects of PA inhibitor.
The up-regulation ofuPA and PAI-2 mRNA suggests that
both cytokines augmented neosynthesis of these proteins
( Figs. 5 and 6). However, in contrast to protein levels, the in-
crease in uPA mRNA was consistently greater in response to
TNF than IFN. The discrepancy between steady-state mRNA
levels and protein expression suggests that other regulatory
mechanisms, such as translational or posttranslational steps
in uPA synthesis, are also differentially affected by these
cytokines. This does not appear to be the case for PAI-2
regulation, as we did not observe notable discrepancies be-
tween stimulated levels ofPAI-2 mRNA, antigen, and activity.
We also observed that PA activity associated with plasma
membrane uPAR was differentially affected by IFN and
TNF. IFN doubled the acid-dissociable PA activity, whereas
TNF had no effect (Fig. 7). By directly measuring receptor-
associated enzymatic activity, we extended previous work in
which uPAR was enumerated by antibody binding alone
[26]. In that study, the number of uPAR was increased by
IFN and to a lesser extent by TNF. However, here we show
that the number of uPAR occupied by endogenously gener-
ated uPA was up-regulated only by IFN. Our results could
be explained in several ways, possibly by up-regulation of
uPAR expression, with IFN inducing a larger response than
TNF. Alternatively, the lower levels of PAI-2 secretion in-
duced by IFN may have permitted greater expression of
receptor-associated PA activity. This could occur either by
less inhibition of the enzyme on the cell surface or by reduc-
tion of inhibitor-mediated internalization of receptor-bound
enzyme [11]. To resolve these issues, it will be necessary to
perform studies of receptor-associated PA enzymatic activity
combined with formal analysis of uPA receptor expression.
This work wiil be particularly important because receptor-
associated uPA may have unique functional properties that
create a propitious site for proteolysis in the immediate
periceilular environment [10, 26, 33].
I I
IFN (U/mi)  TNF(U/mI)
Fig. 7. Effects of IFN and TNF on the level of receptor-associated PA ac-
tivity of U937 cells. IFN doubled receptor-associated PA activity
(tP < .05), while TNF had no effect. Data are expressed in mPU per mu-
lion cells.
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It appears that the U937 cell is a valid model for uPA and
PAI-2 synthesis by authentic mononuclear phagocytes, as the
responses of peripheral blood monocytes to IFN and TNF
effectively duplicated those of U937 cells (Fig. 6). The ab-
sence ofdetectabie PA activity in monocyte supernatants was
the only distinction between the cell types. Although we can-
not state conclusively that a posttranscriptional processing
step prevented expression offunctionai PA activity, it is more
likely that small amounts of secreted uPA were effectively
quenched by PAI-2. U937 cells, being a monoblast-iike
malignant line, could be expected to produce higher levels of
uPA than the more differentiated monocyte [13]. Further-
more, previous studies have suggested that down-regulation
of uPA production and enhanced production of PAI-2 are
features of greater mononuclear phagocyte differentiation
[29, 43].
There is strong evidence that factors regulating immune
and inflammatory responses interact extensively with the
proteins controlling plasmin-mediated fibrinolysis. For ex-
ample, fibrin degradation products are known to be chemo-
taxic for leukocytes, suppressive of lymphocyte function, and
directly injurious to endotheliai cells [12, 15, 38]. As dis-
cussed previously, macrophage PA activity has also been im-
plicated in the activation as well as in the degradation of
growth factors and cytokines [24, 25, 31, 37]. In vitro,
products of stimulated lymphocytes have been shown to reg-
ulate macrophage PA and PA inhibitor activities [18, 40]. In
chronic immune reactions in vivo, there is abnormal regula-
tion and functional expression of local PA and PA inhibitor
proteins [20, 22]. In several murine models of granuioma-
tous inflammation, piasmin-mediated fibrinoiysis is sequen-
tially linked to the inflammatory course of the disease; local
PA inhibitor activity is enhanced as the granulomatous le-
sion evolves, and PA activity appears later as granulomas
regress. This sequential expression was shown to be modu-
lated by T cells [21-23]. Collectively, these observations
strongly suggest that cytokines exert a major influence on
macrophage-derived PA activity in immune reactions and
inflammatory foci. Because we have shown that individual
cytokines can produce distinct profiles of macrophage PA ac-
tivity, it is possible that local piasmin activation is controlled
by phasic changes in cytokine activity during the course of
an inflammatory response. In reciprocal fashion, changes in
plasmin generation could influence the reiease and function
of the same cytokines.
In summary, we have demonstrated that IFN and TNF
stimulate both PA and PA inhibitor activities in mono-
nuclear phagocytes. There are potentially important distinc-
tions between the effect of these cytokines, as IFN elicits a
profile of secreted and receptor-associated activities that sur-
passes TNF in promoting plasminogen activation. By fur-
ther characterizing the factors regulating PA expression, we
hope to elucidate the complex mechanisms by which fibri-
nolysis is integrated with the pathogenesis of specific immu-
nity and inflammation.
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